Reported 6,093,291 shares, down 84,820 (1.4%) from the prior quarter.
Reported value 2.6%; share count -1.4% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2024-03-31 | 93949644 |
| 2024-06-30 | 204105244 |
| 2024-09-30 | 240993936 |
| 2024-12-31 | 286633075 |
| 2025-03-31 | 218458005 |
| 2025-06-30 | 224172176 |
| 2025-09-30 | 290627690 |
| 2025-12-31 | 529226699 |
| 2026-03-31 | 647267117 |
| 2026-06-30 | 1191348571 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q2 2026 | Reduced | 6,361,323 | -294,380 (-4.4%) | 22.31% | $1,191,348,571 | 2026-08-14 | |
| Q1 2026 | Added | 6,655,703 | +11,300 (0.2%) | 13.23% | $647,267,117 | 2026-05-15 | |
| Q4 2025 | Added | 6,644,403 | +421,112 (6.8%) | 13.51% | $529,226,699 | 2026-02-17 | |
| Q3 2025 | Added | 6,223,291 | +130,000 (2.1%) | 8.27% | $290,627,690 | 2025-11-14 | |
| Q2 2025 | Reduced | 6,093,291 | -84,820 (-1.4%) | 9.57% | $224,172,176 | 2025-08-14 | |
| Q1 2025 | Reduced | 6,178,111 | -375,000 (-5.7%) | 10.01% | $218,458,005 | 2025-05-15 | |
| Q4 2024 | Added | 6,553,111 | +1,239,022 (23.3%) | 9.97% | $286,633,075 | 2025-02-14 | |
| Q3 2024 | Added | 5,314,089 | +55,000 (1.0%) | 8.15% | $240,993,936 | 2024-11-14 | |
| Q2 2024 | Added | 5,259,089 | +2,344,114 (80.4%) | 7.81% | $204,105,244 | 2024-08-14 | |
| Q1 2024 | New | 2,914,975 | +2,914,975 (0.0%) | 3.31% | $93,949,644 | 2024-05-15 |
Who else reported the position
343 managers reported REVOLUTION MEDICINES INC for Q2 2025.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | Reduced | 15,761,691 | -850,344 | < 0.01% | $579,872,613 | 22 qtrs |
| FARALLON CAPITAL MANAGEMENT LLC | Added | 14,325,692 | +791,000 | 2.21% | $527,042,209 | 18 qtrs |
| JANUS HENDERSON GROUP PLC | Added | 10,590,727 | +400,656 | 0.19% | $389,682,579 | 11 qtrs |
| WELLINGTON MANAGEMENT GROUP LLP | Reduced | 10,259,738 | -1,528,183 | 0.07% | $377,455,760 | 22 qtrs |
| BAKER BROS ADVISORS LP | Added | 9,364,972 | +1,428,000 | 3.34% | $344,537,320 | 18 qtrs |
| BlackRock Inc | Reduced | 8,661,393 | -6,030,999 | < 0.01% | $318,652,648 | 4 qtrs |
| FMR LLC | Added | 8,325,184 | +789,413 | 0.02% | $306,283,536 | 22 qtrs |
| Nextech Invest Ltd | Unchanged | 7,601,087 | 0 | 52.92% | $279,643,991 | 2 qtrs |
| Paradigm Biocapital Advisors LP This report | Reduced | 6,093,291 | -84,820 | 9.57% | $224,172,176 | 6 qtrs |
| BVF INC IL | Unchanged | 4,982,384 | 0 | 6.55% | $183,301,907 | 22 qtrs |
Filing details and methodology As reported
- Report period
- June 30, 2025
- Filed
- August 14, 2025
- Filing type
- 13F-HR
- Position type
- COM
Voting authority reported
- Sole
- 6,093,291
- Shared
- 0
- None
- 0
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.